

13th March, 2023

To,
The Manager - Corporate Relationship Dept.
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001

To,
The Manager - Corporate Compliance
National Stock Exchange of India Limited
Exchange Plaza, Plot No.C-1,
G Block,BKC, Bandra (E),
Mumbai 400 051

Scrip Code: BSE - 524500

Scrip Code: NSE - KILITCH

Sub: Clarification

Dear Sir,

We reference to your email dated 10th March, 2023, we would like to inform you that the UDIN was generated as per requirement with respect to Limited Review Report on financial results for the quarter ended 31st March, 2023 but the same is remained to mentioned unintentionally in the said report. The report mentioning the UDIN is enclosed herewith for your reference.

We kindly request you to consider our sincere apology and take the attached file on record.

Thanking you,

Yours Faithfully,

For **KILITCH DRUGS (INDIA) LIMITED**

MUKUND MEHTA
MANAGING DIRECTOR
DIN: 00147876





Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of Kilitch Drugs (India) Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended

To,

**The Board of Directors of
Kilitch Drugs (India) Limited**

1. We have reviewed the accompanying statement of "Unaudited Standalone Financial Results" of **Kilitch Drugs (India) Limited** (the 'Company') for the quarter and nine months ended 31st December, 2022 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition & measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulation, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **SURYAPRAKASH MAURYA & Co.**

Chartered Accountants

Firm Registration No. 147410W

(Suryaprakash Maurya)

Proprietor

Membership No. 178258

UDIN: 23178258B5V49D7966



Place : Mumbai

Dated: February 14, 2023



Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of Kilitch Drugs (India) Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of
Kilitch Drugs (India) Limited

1. We have reviewed the accompanying statement of "Unaudited Consolidated Financial Results" of **Kilitch Drugs (india) Limited** ("the Parent"), and its' subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and nine months ended 31st December, 2022 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This statement which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). This Standard requires that we plan and perform the review to obtain moderate assurance as to whether Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, to the extent applicable.

4. The Statement includes the results of entities as given below:

List of Subsidiaries:

1. Monarchy Healthserve Private Limited
 2. Kilitch Estro Biotech PLC – Foreign Subsidiary
5. We did not review the interim financial results and other financial information in respect of one subsidiary whose interim financial results/information reflects, total revenues of Rs.0.31 Lakhs and Rs.0.31 Lakhs for quarter and nine months ended December 31, 2022 respectively, total Net Profit/(Loss) after tax of Rs. (21.42) Lakhs and Rs. (65.34) Lakhs for quarter and nine months ended December 31, 2022 respectively, total comprehensive income/(loss) of Rs. (21.42) Lakhs and Rs.(65.34)Lakhs for the quarter and nine months ended 31st December, 2022. These interim financial results and other financial information have been reviewed by other auditors, whose reports have



been furnished to us by the management of the Company and our conclusion in so far as it relates to the affairs of such subsidiary is based solely on the report of other auditors.

6. The Statement includes interim financial results and other financial information in respect of one foreign subsidiary which reflects, total revenues of Rs.166.95 Lakhs and Rs.2,009.54 Lakhs for quarter and nine months ended December 31, 2022 respectively, total Net Profit/(Loss) after tax of Rs. (200.84) Lakhs and Rs. (455.51) Lakhs for quarter and nine months ended December 31, 2022 respectively, total comprehensive income/(loss) of Rs. (200.84) Lakhs and Rs.(455.51)Lakhs for the quarter and nine months ended 31st December, 2022 as considered in the consolidated financial results. These financial statements have been furnished to us by the management and our opinion on the statement, in so far as it relates to the amounts included in respect of this subsidiary is solely based on such unaudited financial statements as certified by the management. Our conclusion on the Statement is not modified in respect of the above matter.
7. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on management certified financial statements referred in paragraph 6 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For SURYAPRAKASH MURYA & Co.

Chartered Accountants

Firm Registration No. 147410W



(Suryaprakash Maurya)

Proprietor

Membership No. 178258

UDIN: 23178258B4VU8E1031



Place : Mumbai

Dated: February 14, 2023

KILITCH DRUGS (INDIA) LIMITED

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/NINE MONTHS ENDED 31ST DECEMBER, 2022

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701
Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com
CIN:L24239MH1992PLC066718


(Rs. In Lakhs except Earnings per Share data)

Sr. No.	Particulars	Three Months Ended			Nine Months Ended		Year Ended
		31/12/2022	30/09/2022	31/12/2021	31/12/2022	31/12/2021	31/03/2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	Net Sales/ Income from operations	2,850.34	2,242.85	3,056.36	7,450.08	7,312.91	10,515.98
	Other Income	111.30	66.07	171.99	316.58	379.05	455.90
	Total Income	2,961.64	2,308.92	3,228.35	7,766.66	7,691.96	10,971.88
2	Expenses						
	(a) Cost of Materials Consumed	1,283.39	969.13	1,877.14	3,411.39	4,251.09	6,028.55
	(b) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	28.13	(18.07)	19.33	50.17	3.06	(4.69)
	(c) Employee Benefit Expenses	191.45	180.08	156.02	530.29	452.57	615.45
	(d) Finance Cost	27.67	22.85	23.50	57.80	48.56	66.27
	(e) Depreciation and Amortisation Expenses	37.83	31.34	23.83	96.40	70.54	96.42
	(f) Export Product Registration/Commission	215.63	204.73	120.22	588.65	419.76	542.79
	(g) Other Expenses	710.19	592.67	628.95	1,820.94	1,484.45	2,234.27
	Total Expenses	2,494.29	1,982.73	2,848.99	6,555.64	6,730.03	9,579.06
3	Profit / (Loss) before Exceptional items (1-2)	467.35	326.19	379.36	1,211.02	961.93	1,392.82
4	Exceptional Items	-	-	-	-	-	-
5	Profit / (Loss) from ordinary activities before tax (3+4)	467.35	326.19	379.36	1,211.02	961.93	1,392.82
6	Less: Tax Expenses:-						
	Current Tax - [Refer Note No. 4]	144.50	(56.74)	104.93	215.76	220.32	363.37
	Deferred Tax	(70.14)	18.44	(2.35)	(63.68)	(8.84)	(23.32)
7	Net Profit / (Loss) after Tax for the period from Continuing Operations (5-6)	392.99	364.49	276.78	1,058.94	750.45	1,052.77
8	Other Comprehensive Income (after tax)	40.48	142.64	(48.28)	(37.02)	235.44	198.15
9	Total Comprehensive Income (after taxes) (7+8)	433.47	507.13	228.50	1,021.92	985.89	1,250.92
10	Paid-Up equity share capital (Face Value Rs 10 per share)	1,558.23	1,558.23	1,558.23	1,558.23	1,558.23	1,558.23
11	Other Equity						16,244.89
12	Earning per share (not annualised)						
	(a) Basic	2.53	2.34	1.77	6.80	4.82	6.76
	(b) Diluted	2.53	2.34	1.77	6.80	4.82	6.76

Notes:

- The above Unaudited Financial Results of the Company for the quarter/nine months ended 31st December, 2022 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 14th February, 2023
- The Statement has been prepared in accordance with companies (Indian Accounting Standards) Rule, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The Company is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
- The Current Tax for the quarter ended 30th September, 2022 and nine months ended 31st December, 2022 is net off the Tax adjustments of earlier years aggregating to Rs. (124.24) Lakhs.
- Previous period figures have been regrouped and reclassified wherever necessary.

Place : Mumbai
Dated: 14th February, 2023



For and on behalf of the Board of Directors

Mukund Mehta



Mukund Mehta
Managing Director
DIN: 00147876



KILITCH DRUGS (INDIA) LIMITED
CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/NINE MONTHS ENDED 31ST DECEMBER, 2022

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701
 Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com
 CIN:L24239MH1992PLC066718

Sr.No.	Particulars	Three Months Ended			Nine Months Ended			Year Ended	
		31-12-22	30-09-22	31-12-21	31-12-22	31-12-21	31-03-22	Audited	Audited
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited		
1	Income Net Sales/Income from Operations Other Income Total Income	2,997.23 68.66 3,065.89	3,069.70 23.96 3,093.66	3,443.13 130.91 3,574.04	9,412.19 189.76 9,601.95	7,762.67 253.10 8,015.77	11,423.42 290.93 11,714.35		
2	Expenses Cost of Materials Consumed Changes in inventories of finished goods, work-in-progress and Stock-in-Trade Employee Benefit Expenses Finance Cost Depreciation and Amortisation Expenses Export Product Registration/Commission Other expenses Total Expenses	1,336.64 28.13 297.76 128.85 92.71 218.76 717.92 2,820.77	1,558.36 (18.07) 307.59 175.19 88.66 207.64 618.91 2,938.28	2,063.50 36.25 156.69 23.50 19.66 120.22 990.36 3,410.17	4,871.15 50.17 884.30 371.19 263.63 599.56 1,871.74 8,911.74	4,492.16 3.06 454.75 48.56 133.87 419.76 1,860.75 7,412.89	6,548.03 (4.69) 618.31 119.84 246.56 548.13 2,676.73 10,752.91		
3	Profit before Exceptional items (1-2)	245.12	155.38	163.87	690.21	602.88	961.44		
4	Exceptional Items								
5	Profit from ordinary activities before tax (3+4)	245.12	155.38	163.87	690.21	602.88	961.44		
6	Less : Tax Expenses Current Income Tax [Refer Note No. 4] Deferred Tax	144.50 (70.19) 170.81	(56.74) 18.47 193.65	104.93 (2.35) 61.29	215.76 (63.70) 538.15	220.32 (8.83) 391.39	363.37 (23.30) 621.37		
7	Profit after tax for the period from continuing operations (5-6) Add/(Less) : Share in Profits / (Loss) of Associates								
8	Net Profit/(Loss) After Tax & Share in Profits / (Loss) of Associates	170.81	193.65	61.29	538.15	391.39	621.37		
9	Other Comprehensive Income (after Tax)	40.48	142.64	(48.28)	(37.02)	235.44	198.15		
10	Total Comprehensive Income (after taxes) (8+9)	211.29	336.29	13.01	501.13	626.83	819.52		



11	Net Profit / (Loss) attributable to a) Owner of the Company b) Non Controlling interest	237.07 (66.26)	242.78 (49.13)	112.49 (51.20)	688.47 (150.32)	446.91 (55.52)	736.73 (115.36)
12	Other Comprehensive Income attributable to a) Owner of the Company b) Non Controlling interest	40.48 -	142.64 -	(48.28) -	(37.02) -	235.44 -	198.15 -
13	Total Income attributable to a) Owner of the Company b) Non Controlling interest	277.55 (66.26)	385.42 (49.13)	64.21 (51.20)	651.45 (150.32)	682.35 (55.52)	934.88 (115.36)
14	Paid-Up equity share capital (Face Value Rs. 10 per share)	1,558.23	1,558.23	1,558.23	1,558.23	1,558.23	1,558.23
15	Other Equity	-	-	-	-	-	12,350.41
16	Earning per share (not annualised) (a) Basic (b) Diluted	1.52 1.52	1.56 1.56	0.72 0.72	4.42 4.42	2.87 2.87	4.73 4.73

Notes:

- The above unaudited Consolidated Financial Results the Company for the quarter/nine months ended 31st December, 2022 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 14th February, 2023.
- The Statement has been prepared in accordance with companies (Indian Accounting Standards) Rule, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The Group is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
- The Current Tax for the quarter ended 30th September, 2022 and nine months ended 31st December, 2022 is net off the Tax adjustments of earlier years aggregating to Rs. (124.24) Lakhs.
- Previous period figures have been regrouped and reclassified wherever necessary.

Place: Mumbai
Date: 14th February, 2023

For and on behalf of the Board of Directors:

Mukund Mehta
Managing Director
DIN: 00147876

